GMP IPO Watch
Baroda BNP Paribas Health and Wellness Fund
Regular Plan · Growth Option · Baroda BNP Paribas Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.53% | +3.52% | 164 of 255 |
| 1M | +2.77% | +1.97% | 89 of 255 |
| 3M | -0.36% | -3.45% | 43 of 252 |
| 6M | +11.53% | +2.92% | 40 of 251 |
| YTD | +13.73% | +1.21% | 32 of 255 |
| 1Y | +10.59% | +1.11% | 39 of 232 |
| INCEPTION | +5.41% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +1.92% | +16.68% | -8.27% | 46% | 18% |
| 6M | +4.49% | +21.39% | -11.89% | 61% | 24% |
| 1Y | +7.60% | +13.08% | +0.83% | 100% | 42% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity97.06%
- Debt0.00%
- Cash2.94%
- Other0.00%
Market Cap Split
- Large Cap31.13%
- Mid Cap46.33%
- Small Cap19.60%
- Others2.94%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 40.70 | 41.94 |
| P/B | 7.29 | 6.29 |
| Price / Sales | 5.35 | 6.05 |
| Price / Cash Flow | 31.39 | 31.26 |
| Dividend Yield (%) | 0.65 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 8.58% | -0.43% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 7.88% | -0.11% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 7.82% | -0.19% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 6.13% | -0.10% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 6.09% | +0.43% |
| Lupin | Pharmaceuticals & Biotechnology | 5.79% | -0.20% |
| Apollo Hospitals | Equity | 5.28% | -0.16% |
| Fortis Healthcare | Equity | 3.98% | -0.52% |
| Dr. Lal Path Labs | Equity | 3.47% | +0.23% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 3.34% | +0.24% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.11% | -0.31% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 3.09% | +0.04% |
| AstraZeneca Pharma | Pharmaceuticals & Biotechnology | 2.79% | -0.77% |
| Clearing Corporation of India Ltd | Net Current Assets | 2.78% | — |
| Abbott | Pharmaceuticals & Biotechnology | 2.50% | +0.21% |
View all 35 holdings
| Emcure Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.39% | +0.01% |
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 2.36% | +0.12% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.24% | +0.09% |
| Max Financial Services | Insurance | 2.21% | -0.22% |
| Aster DM Quality Care | Equity | 2.15% | -0.08% |
| Concord Biotech | Pharmaceuticals & Biotechnology | 2.11% | -0.03% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.56% | +0.07% |
| Symbiotec Pharmalab | Pharmaceuticals & Biotechnology | 1.47% | +0.29% |
| Nephrocare Health Services | Equity | 1.42% | +0.07% |
| Metropolis Healthcare | Equity | 1.33% | -0.16% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 1.26% | +0.12% |
| Manipal Health Enterprises | Equity | 1.23% | -0.04% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 1.19% | +0.05% |
| Cipla | Pharmaceuticals & Biotechnology | 1.10% | -0.01% |
| Narayana Hrudayalaya | Equity | 0.97% | — |
| Inventurus Knowledge Solutions | IT - Services | 0.90% | +0.05% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.68% | -0.04% |
| LIC of India | Insurance | 0.47% | -0.01% |
| Procter & Gamble Health | Pharmaceuticals & Biotechnology | 0.17% | -0.40% |
| Net Receivables / (Payables) | Net Current Assets | 0.16% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 12.47 | 16.32 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.34 | -0.32 | Above Average |
| 3Y | -0.10 | -0.45 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.29 | 0.19 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.85 | 0.96 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From Baroda BNP Paribas Asset Management India Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Baroda BNP Paribas Gold ETF
Regular Plan · Growth Option
|
+16.72% | — | — | +31.58% |
|
Baroda BNP Paribas Gold ETF Fund of Fund
Direct Plan · Growth Option
|
+16.34% | — | — | +32.15% |
|
Baroda BNP Paribas Aqua Fund of Fund
Direct Plan · IDCW Option
|
+15.77% | +16.69% | — | +12.53% |
|
Baroda BNP Paribas Innovation Fund
Direct Plan · IDCW Option
|
+7.95% | — | — | +13.82% |
|
Baroda BNP Paribas Credit Risk Fund (scheme has Two segregated portfolios)
Direct Plan · Growth Option
|
+7.05% | +8.36% | +9.33% | +8.73% |
|
BARODA BNP PARIBAS LIQUID FUND
Direct Plan · Growth Option
|
+6.45% | +6.87% | +6.43% | +6.87% |
|
Baroda BNP Paribas Ultra Short Term Fund
Direct Plan · Growth Option
|
+6.41% | +7.14% | +6.69% | +6.49% |
|
Baroda BNP Paribas Money Market Fund
Direct Plan · Growth Option
|
+6.35% | +7.19% | +6.51% | +5.87% |
|
Baroda BNP Paribas Manufacturing Fund
Direct Plan · IDCW Option
|
+6.31% | — | — | +3.47% |
|
Baroda BNP Paribas Multi Asset Active Fund of Funds
Direct Plan · Growth Option
|
+6.30% | — | — | +9.26% |
About This Scheme
Investment Objective
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Stated Asset Allocation
Equity & equity related instruments of companies in the Pharma & Healthcare and allied sector- 80-100%Equity and equity related instruments of companies other than above- 0-20%Money Market and other liquid instruments*, Gold and Silver instruments (through ETFs) - 0-20% Units of Mutual Funds as permitted by SEBI- 0-10% Units issued by InvITs - 0-10%
Exit Load
Redemption/ switch out of units upto 10% of the units allotted before 1 year from date of allotment- Exit load -NIL For redemption/switch out of units above 10% of units allotted within 1 year from the date of allotment- 1.00% of applicable NAV For redemption/switch out of units after 1 year from the date of allotment-Nil
Fund Managers
Mr. Rohan Korde, Mr. Ankeet Pandya
Primary, Primary
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.